As discussed above, to encounter PERK activation in TKIs-treated RCC, Stokes et al. discovered that PERK inhibitor HC-5404 enhanced the antiangiogenic effects of axitinib and lenvatinib. The gene discussed is EIF2AK3; the disease is renal cell adenocarcinoma.